AstraZeneca PLC (LON:AZN)
| Market Cap | 217.67B +3.8% |
| Revenue (ttm) | 46.99B +7.3% |
| Net Income | 8.31B +17.4% |
| EPS | 5.32 +17.3% |
| Shares Out | 1.55B |
| PE Ratio | 26.39 |
| Forward PE | 16.67 |
| Dividend | 2.39 (1.70%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 2,286,583 |
| Open | 14,056 |
| Previous Close | 13,982 |
| Day's Range | 13,964 - 14,222 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.16 |
| Analysts | Buy |
| Price Target | 16,308.15 (+16.21%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,308p, which is an increase of 16.21% from the latest price.
News
AstraZeneca PLC Announces Baxfendy Recommended for Approval in the EU
AstraZeneca PLC announced that Baxfendy has been recommended for approval in the European Union for the treatment of adults with arterial hypertension insufficiently controlled with at least two antih...
AstraZeneca PLC Receives US FDA Approval for Imfinzi Combination in Muscle-Invasive Bladder Cancer
AstraZeneca PLC announced that the US Food and Drug Administration has approved Imfinzi in combination with enfortumab vedotin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant tre...
AstraZeneca PLC Announces EU Approval of Klygefa for Generalised Myasthenia Gravis
AstraZeneca PLC announced that the European Commission has approved Klygefa (gefurulimab) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are an...
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
AstraZeneca's Alexion Pharmaceuticals on Monday defeated a proposed class-action lawsuit in Massachusetts federal court that had accused it of misusing its patents to maintain a monopoly on its blockb...
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
AstraZeneca Cuts 600 U.S. Sales Jobs At Cost-Saving Program Takes Effect
(RTTNews) - AstraZeneca (AZN) has cut approximately 600 jobs from its U.S. respiratory and immunology commercial teams, as part of a broader restructuring and cost-savings initiative, Bloomberg report...
AstraZeneca, Alexion announce Klygefa approved in EU
Alexion and AstraZeneca (AZN) Rare Disease’s Klygefa has been approved in the European Union, EU, as an add-on to standard therapy for the treatment of generalised myasthenia gravis, gMG, in…
AstraZeneca: Alexion's Klygefa Gets EU Approval To Treat Adults With Generalised Myasthenia Gravis
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Monday that Klygefa (gefurulimab), from Alexion, AstraZeneca Rare Disease, has been approved in the European Union for the treatme...
AZN : FDA Okays IMFINZI Combination Regimen For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
(RTTNews) - AstraZeneca (AZN) has secured U.S. Food and Drug Administration approval for its immunotherapy IMFINZI (durvalumab) in combination with enfortumab vedotin-ejfv as a perioperative treatment...
AstraZeneca announces FDA approval of imfinzi/EV combination
AstraZeneca’s (AZN) imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by imfinzi monotherapy as adjuvant treatment after radical cystectomy, has been approved in t...
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatmen...
AstraZeneca’s Alexion receives FDA approval for Klygefa
Klygefa is indicated for the treatment of generalized myasthenia gravis in adult patients who are antiacetylcholine receptor antibody positive, according to prescribing information posted to the agenc...
FDA approves AstraZeneca combo treatment for bladder cancer
The Food and Drug Administration said it approved AstraZeneca’s (AZN) Imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant trea...
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
AstraZeneca cuts 600 sales jobs in U.S., Bloomberg reports
AstraZeneca (AZN) cut about 600 jobs from its respiratory and immunology commercial teams in the U.S., Ashleigh Furlong of Bloomberg reports, citing people familiar with the matter. Some of cut…
EU panel backs AstraZeneca hypertension drug baxdrostat
AstraZeneca said on Friday a European medicines committee had backed its hypertension pill baxdrostat, branded as Baxfendy, for marketing authorisation, potentially making it the first drug of its c...
AstraZeneca announces EMA’s CHMP recommends approval of Baxfendy
AstraZeneca’s (AZN) Baxfendy has been recommended for approval in the European Union, EU, for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihyperte...
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative....
AstraZeneca Gains Single-Cell Bioconjugation Technology Through Omniose Deal
(RTTNews) - AstraZeneca PLC (AZN) has acquired Omniose, a preclinical biotechnology company developing vaccines against serious bacterial infections.
AstraZeneca Acquires Omniose Following Three-Year Research Collaboration
(RTTNews) - AstraZeneca(AZN), has acquired Omniose, a St. Louis-based preclinical biotechnology company, making it a wholly owned subsidiary within its Infectious Disease Unit.
AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition
AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target ...
Omniose Announces Its Acquisition by AstraZeneca
ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research c...
What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHZimmer Biomet (NYSE:ZBH) raised its 2026 sales growth and adjusted earnings outlook after third-quarter growth in hips, surgical specialt...
Edwards Lifesciences Q3 Earnings Call Highlights
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations...
US measles status to go up for review
Presented by AstraZeneca {beacon} Healthcare Healthcare The Big Story US measles status to go up for review The U.S. and Mexico will meet with the Pan American Health Organization (PAHO) for a three-d...